SF3B1 and acute myeloid leukemia: This change is based largely on results from a study comparing the genetic profiles of de novo AML and rigorously clinically defined sAML in which the presence of mutations SRSF2,SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, or STAG2 was highly specific for a diagnosis of sAML (50).